Australia and New Zealand Transplant and Cellular Therapies COVID_19 vaccination consensus position statement
Type
ArticleAuthor/s
Hamad, NadaAnanda_Rajah, Michelle
Gilroy, Nicole
MacIntyre, Raina
Gottlieb, David
Ritchie, David
Harrison, Simon
Kennedy, Glen
Watson, Anne M.
Greenwood, Matthew
Doocey, Richard
Perera, Travis
Spencer, Andrew
Wong, Eric
O'Brien, Tracey
Shaw, Peter
Conyers, Rachel
Milliken, Samuel
Bardy, Peter
Larsen, Stephen
Ho, Phoebe J.
Lai, Hock
Bajel, Ashish
Butler, Jason
Tiley, Campbell
D'Rozario, James
Johnston, Anna
Cochrane, Tara
Mills, Tony
Irving, Ian
Pullon, Humprey
Purtill, Duncan
Abstract
Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives of all adult and paediatric allogeneic bone marrow transplant and cellular therapy (TCT) centres as ...
See moreAustralia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives of all adult and paediatric allogeneic bone marrow transplant and cellular therapy (TCT) centres as well as representatives from autologous transplant only centres in Australia and New Zealand collaborated with infectious diseases specialists with expertise in TCT on this consensus position statement regarding COVID-19 vaccination in TCT patients in Australia and New Zealand. It is our recommendation that TCT patients, should have expedited access to high-efficacy COVID-19 vaccines given that these patients are at high risk of morbidity and mortality from COVID-19 infection. We also recommend prioritising vaccination of TCT healthcare workers and household members of TCT patients. Vaccination should not replace other public health measures in TCT patients given the effectiveness of COVID-19 vaccination in TCT patients is unknown. Furthermore, given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.
See less
See moreAustralia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives of all adult and paediatric allogeneic bone marrow transplant and cellular therapy (TCT) centres as well as representatives from autologous transplant only centres in Australia and New Zealand collaborated with infectious diseases specialists with expertise in TCT on this consensus position statement regarding COVID-19 vaccination in TCT patients in Australia and New Zealand. It is our recommendation that TCT patients, should have expedited access to high-efficacy COVID-19 vaccines given that these patients are at high risk of morbidity and mortality from COVID-19 infection. We also recommend prioritising vaccination of TCT healthcare workers and household members of TCT patients. Vaccination should not replace other public health measures in TCT patients given the effectiveness of COVID-19 vaccination in TCT patients is unknown. Furthermore, given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.
See less
Date
2021Share